Garry Arthur Neil
CIK 1586785 · Chief Executive Officer · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GNMX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1500 LIBERTY RIDGE DRIVE, SUITE 321
WAYNE, PA 19087
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLDX | Director | — | $29.82 | — | $0 | 5 | 2026-06-29 |
| AVTX | Chief Executive Officer | 190,314 | $6.76 | $1.29M | $29.6K | 12 | 2026-05-26 |
| Zura Bio Ltd (ZURAW) Delisted | Director | — | $1.08 | — | $0 | 1 | 2023-05-22 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | Director | 0 | $99.99 | $0 | $0 | 7 | 2022-03-11 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Scientific Officer | 81,372 | $2.93 | $238.4K | $20.7K | 5 | 2021-06-14 |
| GNMX | Chief Scientific Officer | 2,164,150 | $36.79 | $79.62M | $369.1K | 7 | 2019-12-09 |
| Oncternal Therapeutics, Inc. (GTXI) Delisted | Director | 5,251 | — | — | $0 | 14 | 2019-01-03 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Chief Scientific Officer | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Chief Scientific Officer | 39,774 | — | — | $200.0K | 4 | 2015-10-08 |
Recent Filings · Page 5 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-04 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | +1,574 | $12.5K | EDGAR |
| 2017-08-15 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | +2,376 | $12.5K | EDGAR |
| 2017-06-14 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-15 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-05 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | +2,551 | $12.5K | EDGAR |
| 2017-02-17 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2017-02-14 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | +2,399 | $12.5K | EDGAR |
| 2016-10-04 | Oncternal Therapeutics, Inc. (GTXI) Delisted | Grant (A) | +16,447 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.